Cargando…

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic

Psoriasis is a chronic inflammatory skin disease that affects up to 1.2% of children and adolescents. The treatment options for childhood psoriasis are often based on the same principles as in adults. However, most data on safety and efficacy derive from adult studies, and only a few of the frequent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haulrig, Morten B, Zachariae, Claus, Skov, Lone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886293/ https://www.ncbi.nlm.nih.gov/pubmed/33604269 http://dx.doi.org/10.2147/PTT.S268462

Ejemplares similares

Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

Cohort profile: the clinical ‘Psoriasis in Adolescents’ (PIA) cohort in Denmark
por: Blegvad, Christoffer, et al.
Publicado: (2019)

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report
por: Haulrig, Morten Bahrt, et al.
Publicado: (2022)

Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study
por: TODBERG, Tanja, et al.
Publicado: (2020)

Musculoskeletal Pain in Patients with Psoriasis and its Influence on Health-related Quality of Life: Results from a Danish Populationbased Survey
por: FELBO, Sara Kamp, et al.
Publicado: (2021)

Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
por: Kvist-Hansen, Amanda, et al.
Publicado: (2019)

Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c Levels
por: SCHWARZ, Christopher Willy, et al.
Publicado: (2020)

Can patient-reported outcome measures be used to predict consultation needs in patients with psoriasis?: A survey study
por: Krontoft, Anna Sophie Belling, et al.
Publicado: (2022)

Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis
por: Andersen, Clara Sophie Bramsen, et al.
Publicado: (2023)

Neutrophil Pathways of Inflammation Characterize the Blood Transcriptomic Signature of Patients with Psoriasis and Cardiovascular Disease
por: Kvist-Hansen, Amanda, et al.
Publicado: (2021)

Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review
por: TODBERG, Tanja, et al.
Publicado: (2021)

Association between Vascular Inflammation and Inflammation in Adipose Tissue, Spleen, and Bone Marrow in Patients with Psoriasis
por: Kaiser, Hannah, et al.
Publicado: (2021)

Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study
por: TODBERG, Tanja, et al.
Publicado: (2020)

Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review
por: AMIRI, Diva, et al.
Publicado: (2023)

Multiscale Biology of Cardiovascular Risk in Psoriasis: Protocol for a Case-Control Study
por: Kaiser, Hannah, et al.
Publicado: (2021)

Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
por: Todberg, Tanja, et al.
Publicado: (2020)

Development and preliminary validation of the Adolescent Psoriasis Quality of Life instrument: a disease‐specific measure of quality of life in adolescents with psoriasis
por: Randa, H., et al.
Publicado: (2020)

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)
por: Gyldenløve, Mette, et al.
Publicado: (2023)

Side effects after artificial hair implants: 2 case reports
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

The off-label use of anakinra in pediatric systemic autoinflammatory diseases
por: Maniscalco, Valerio, et al.
Publicado: (2020)

Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations
por: Belayneh, Anteneh, et al.
Publicado: (2020)

Pediatric psoriasis: an update
por: Silverberg, Nanette B
Publicado: (2009)

Salivary microbiota and inflammation‐related proteins in patients with psoriasis
por: Belstrøm, Daniel, et al.
Publicado: (2020)

Hydroxychloroquine/oseltamivir: Exacerbation of psoriasis during off-label use: case report
Publicado: (2020)

Systemic Treatment of Pediatric Psoriasis: A Review
por: Napolitano, Maddalena, et al.
Publicado: (2016)

Azithromycin/hydroxychloroquine off label use: Pustular psoriasis following misuse: case report
Publicado: (2022)

Off-label drugs use in pediatric palliative care
por: De Zen, Lucia, et al.
Publicado: (2018)

Recommendations on Off-Label Drug Use in Pediatric Guidelines
por: Meng, Min, et al.
Publicado: (2022)

Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis
por: Cline, Abigail, et al.
Publicado: (2019)

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
por: Narbutt, Joanna, et al.
Publicado: (2023)

Development and internal validation of a diagnostic prediction model for psoriasis severity
por: Liljendahl, Mie Sylow, et al.
Publicado: (2023)

Traditional and Non-traditional Cardiovascular Risk Factors and Cardiovascular Disease in Women with Psoriasis
por: NÄSLUND-KOCH, Charlotte, et al.
Publicado: (2022)

Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors
por: Pin, Alessia, et al.
Publicado: (2020)

Utilisation of drugs for the treatment of psychiatric diseases in the pediatric population: focus on off-label use
por: Pesiou, Stella, et al.
Publicado: (2023)

Pediatric Psoriasis: From New Insights into Pathogenesis to Updates on Treatment
por: Kim, Hye One, et al.
Publicado: (2021)

Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives
por: Diotallevi, Federico, et al.
Publicado: (2022)

The update of treatment strategies in pediatrics with generalized pustular psoriasis in China
por: Chen, Yunliu, et al.
Publicado: (2023)

Off-label use of canakinumab in pediatric rheumatology and rare diseases
por: Del Giudice, Emanuela, et al.
Publicado: (2022)

Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities
por: Campanati, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pc1p6ob07levsudkvqkr7avpjk